Retinal Medicine Clinical Research Grant 2021/2022

Apply for Grant

The EURETINA Retinal Medicine Clinical Research Award is an annual initiative sponsored by EURETINA to support and encourage independent clinical research in the field of retinal medicine.

Clinical research, as proposed by clinician or non-clinician researchers, may conduct several types of clinical research, such as observational research studies, register studies (patient or disease registry), natural history / epidemiological studies, phase IV studies (post-authorisation safety studies, “PASS”), genomic research studies, pharmacovigilance studies, retrospective case-control studies, systematic reviews, meta-analyses and several other types of clinical studies.

The 2022 Clinical Research Call aims to fund up to six research projects. The maximum amount that might be awarded to a successful applicant is €300K, always subject to the quality of the research proposal and the benefits for patients.

The competition is open to all clinicians and researchers, who hold EURETINA membership on the closing date (7th March 2022) and have held (continuous) EURETINA membership since at least April 2021, holding a full time clinical/research post at an EU-based clinical or academic centre including H2020 associated countries* and UK.  Please see further eligibility criteria below.

*(Iceland, Norway, Albania, Bosnia and Herzegovina, the former Yugoslav Republic of Macedonia, Montenegro, Serbia, Turkey, Israel, Moldova, Switzerland, Faroe Islands, Ukraine, Tunisia, Georgia, Armenia)

The Purpose of the RMCR Award

– To support, encourage and fund individuals that actively conduct clinical research in the field of retinal medicine.

– To facilitate and support an independent culture of clinical study for the ultimate benefit of patients with retinal disease.

– To engage and encourage the networking potential of the ophthalmic clinical community across the EU (and H2020 associated countries) to improve both patient care and outcomes.

Funding may be available over 2 years (maximum duration) for the right project with suitable infrastructure and experience.

Criteria for applicants:

– Hold a full-time or affiliated post with an established EU-based (and H2020 associated countries) clinical or academic/research institute

– Hold EURETINA membership on the closing date (7th March 2022) and have held (continuous) EURETINA membership since at least April 2021. (obligatory to Principal Applicant only)

– Are not officers on the EURETINA Executive, Board and Trustees. Board Members are permitted to be involved in a project as informal collaborators.  Informal collaborators do not receive funding.  

– Have not previously been awarded funding through the EURETINA Retinal Medicine Clinical Research Award Programme

– Have not previously submitted an identical application for review in the EURETINA Retinal Medicine Clinical Research Award Programme

– Have demonstrable prior experience in the conduct of non-interventional clinical research in the field of retinal medicine and hold demonstrable GCP experience

– Are familiar and experienced with the administrative, insurance and regulatory requirements for the conduct of EU-based clinical research studies

What EURETINA is looking for

The EURETINA Clinical Research Awards are as much to do with good clinical science as they are to do with the capability to execute a solid research project creating near-term clinical impact. Any compelling scientific or medical rationale will need to be matched by an equally compelling infrastructure and research expertise that has been demonstrated to deliver on similar initiatives in the past. The combination of clinical science and clinical research expertise is the key to convincing the EURETINA Research Committee and your peers of a credible and attractive clinical research programme.

All eligible Expressions-of-Interest will be evaluated by the EURETINA Research Call Review Panel, from which short listed entries will be invited to make a full proposal.

Timeline

Date TBC
– Deadline for Expression of Interest

Date TBC
– Shortlisted candidates announced

Date TBC
– Deadline for receipt of shortlisted full applications

Any queries prior to submission of an Expression-of-Interest application should be directed to [email protected]

Terms and Conditions 

(a) I/We hold a full-time or affiliated post with an established EU-based (and H2020 associated countries) clinical or research institute, as named on my Expression-of-Interest submission.

(b) I/We have demonstrable prior experience in the conduct of non-interventional clinical research in the field of retinal medicine and hold demonstrable GCP experience.

(c) I am/We are familiar and experienced with the administrative, insurance and regulatory requirements for the conduct of EU-based clinical research studies.

(d) As Principal Applicant, I am a member of EURETINA for more than 12 months and my EURETINA membership number is included on my Expression-of-Interest submission.

(e) I understand that Expressions-of-Interest will be evaluated by the EURETINA Research Call Review panel, who will generate a short-list of applicants to be invited to make a full comprehensive research proposal to EURETINA. All decisions on Expressions-of-Interest and short-listed proposals made by EURETINA shall be final and no correspondence will be entered into in relation to decisions made.

(f) I understand that officers on the EURETINA Executive, Board and Trustees shall not be eligible to apply for the Expressions-of-Interest.

(g) I understand that awardees from the previous round of the EURETINA Retinal Medicine Clinical Research Award Programme shall not be eligible to apply for the Expressions-of-Interest

(h) I/We understand that resubmission of an identical application from previous rounds of the EURETINA Retinal Medicine Clinical Research Award Programme is not permitted. 

(i) As Principal Applicant, I understand that I am eligible to submit only one Expression-of-Interest

Apply for Grant